Trial Profile
A randomized phase III study in previously untreated patients with biological high-risk CLL [chronic lymphocytic leukaemia]: fludarabine and cyclophosphamide (FC) versus FC and low-dose alemtuzumab
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 17 Aug 2023
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Fludarabine
- Indications Chronic lymphocytic leukaemia
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms HOVON68
- 17 Aug 2023 According to European Clinical Trials Database, the trial is completed in Finland and Czech while its ongoing in Sweden , Denmark and Belgium.
- 12 Dec 2017 Results (n=187) assessing effect of B-cell receptors stereotypy subsets on the primary outcome presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 14 Jun 2013 Results of an analysis that investigated the effects of genetic mutations on outcomes (n=119) presented at the 18th Congress of the European Haematology Association.